WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584349
CAS#: 74711-43-6
Description: Zaltoprofen is a nonsteroidal anti-inflammatory drug with antipyretic and analgesic effects useful for patients with acute upper respiratory tract infection, including those with influenza infection.
MedKoo Cat#: 584349
Name: Zaltoprofen
CAS#: 74711-43-6
Chemical Formula: C17H14O3S
Exact Mass: 298.0664
Molecular Weight: 298.356
Elemental Analysis: C, 68.44; H, 4.73; O, 16.09; S, 10.75
Synonym: Zaltoprofen; CN 100; CN-100; CN100
IUPAC/Chemical Name: 10,11-Dihydro-alpha-methyl-10-oxodibenzo(b,f)thiepin-2-acetic acid
InChi Key: MUXFZBHBYYYLTH-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H14O3S/c1-10(17(19)20)11-6-7-15-12(8-11)9-14(18)13-4-2-3-5-16(13)21-15/h2-8,10H,9H2,1H3,(H,19,20)
SMILES Code: O=C(O)C(C)C1=CC=C(C(C2)=C1)SC3=CC=CC=C3C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 298.356 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Jia L, Hu C, Wang H, Liu Y, Liu X, Zhang YY, Li W, Wang LX, Cao YF, Fang ZZ. Chirality Influence of Zaltoprofen Towards UDP-Glucuronosyltransferases (UGTs) Inhibition Potential. Chirality. 2015 Jun;27(6):359-63. doi: 10.1002/chir.22436. Epub 2015 Apr 22. PubMed PMID: 25903196.
2: Kohno T. Zaltoprofen inhibits bradykinin-mediated enhancement of glutamate receptor activity in substantia gelatinosa neurons. Anesth Analg. 2011 Aug;113(2):412-6. doi: 10.1213/ANE.0b013e31821c693c. Epub 2011 Apr 25. PubMed PMID: 21519044.
3: Baek JS, Lim JH, Kang JS, Shin SC, Jung SH, Cho CW. Enhanced transdermal drug delivery of zaltoprofen using a novel formulation. Int J Pharm. 2013 Sep 10;453(2):358-62. doi: 10.1016/j.ijpharm.2013.05.059. Epub 2013 Jun 4. PubMed PMID: 23747435.
4: Mishra R, Prabhavalkar KS, Bhatt LK. Preparation, optimization, and evaluation of Zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery. J Liposome Res. 2016 Dec;26(4):297-306. doi: 10.3109/08982104.2015.1120746. Epub 2016 Jan 19. PubMed PMID: 26785055.
5: Li L, Ma P, Cao Y, Tao L, Tao Y. Single-dose and multiple-dose pharmacokinetics of zaltoprofen after oral administration in healthy Chinese volunteers. J Biomed Res. 2011 Jan;25(1):56-62. doi: 10.1016/S1674-8301(11)60007-9. PubMed PMID: 23554672; PubMed Central PMCID: PMC3596677.
6: Shah HA, Patel RP. Statistical modeling of zaltoprofen loaded biopolymeric nanoparticles: Characterization and anti-inflammatory activity of nanoparticles loaded gel. Int J Pharm Investig. 2015 Jan-Mar;5(1):20-7. doi: 10.4103/2230-973X.147229. PubMed PMID: 25599029; PubMed Central PMCID: PMC4286831.
7: Cui H, Quan P, Zhao H, Wen X, Song W, Xiao Y, Zhao Y, Fang L. Mechanism of Ion-Pair Strategy in Modulating Skin Permeability of Zaltoprofen: Insight from Molecular-Level Resolution Based on Molecular Modeling and Confocal Laser Scanning Microscopy. J Pharm Sci. 2015 Oct;104(10):3395-403. doi: 10.1002/jps.24543. Epub 2015 Jun 17. PubMed PMID: 26349639.
8: Azuma A, Kudoh S, Nakashima M, Nagatake T. Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodium. Pharmacology. 2011;87(3-4):204-13. doi: 10.1159/000324532. Epub 2011 Mar 25. PubMed PMID: 21430410.
9: Pawar S, Pande V. Oleic Acid Coated Gelatin Nanoparticles Impregnated Gel for Sustained Delivery of Zaltoprofen: Formulation and Textural Characterization. Adv Pharm Bull. 2015 Nov;5(4):537-48. doi: 10.15171/apb.2015.073. Epub 2015 Nov 30. PubMed PMID: 26819927; PubMed Central PMCID: PMC4729344.
10: Cho IJ, Lee CW, Lee MY, Kang MR, Yun J, Oh SJ, Han SB, Lee K, Park SK, Kim HM, Jung SH, Kang JS. Differential anti-inflammatory and analgesic effects by enantiomers of zaltoprofen in rodents. Int Immunopharmacol. 2013 Aug;16(4):457-60. doi: 10.1016/j.intimp.2013.05.008. Epub 2013 May 27. PubMed PMID: 23721690.
11: Wang H, Ji J, Zeng S. Biosynthesis and stereoselective analysis of (-)- and (+)-zaltoprofen glucuronide in rat hepatic microsomes and its application to the kinetic analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2430-6. doi: 10.1016/j.jchromb.2011.06.043. Epub 2011 Jul 6. PubMed PMID: 21775222.
12: Chu VM, Kim KT, Kim SH, Lee W, Lee KC, Nguyen VL, Hoang VL, Lee YK, Park KR, Jung SH, Kang JS. Chiral pharmacokinetics of zaltoprofen in rats by HPLC with solid-phase extraction. J Pharm Biomed Anal. 2012 Nov;70:567-73. doi: 10.1016/j.jpba.2012.05.019. Epub 2012 May 23. PubMed PMID: 22703836.
13: Pareek A, Gupta AK, Chandurkar NB, Sirsikar AD, Ambade RE, Jesalpura BH, Swamy AP. Zaltoprofen, a noninferior alternative to diclofenac for the treatment of primary knee osteoarthritis -- a comparative evaluation of efficacy and safety in a 4-week, multicentric, randomized, double-blind, double-dummy trial. Expert Opin Pharmacother. 2011 May;12(7):1007-15. doi: 10.1517/14656566.2011.566867. Epub 2011 Apr 7. PubMed PMID: 21470071.
14: Azuma A, Kudoh S, Nakashima M, Nagatake T. A double-blind study of zaltoprofen for the treatment of upper respiratory tract infection. Pharmacology. 2010;85(1):41-7. doi: 10.1159/000268104. Epub 2009 Dec 19. PubMed PMID: 20029243.
15: Yang HK, Kim SY, Kim JS, Sah H, Lee HJ. Application of column-switching HPLC method in evaluating pharmacokinetic parameters of zaltoprofen and its salt. Biomed Chromatogr. 2009 May;23(5):537-42. doi: 10.1002/bmc.1151. PubMed PMID: 19101928.
16: Mi DF, Zhang ZR, Zhao Y, Gong T, Liu F. [Preparation of sustained-release capsules of zaltoprofen]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2010 Jan;41(1):166-9, 188. Chinese. PubMed PMID: 20369496.
17: Komiya A, Endo T, Kobayashi M, Kim W, Araki K, Naya Y, Suzuki H, Tobe T, Ichikawa T, Fuse H. Oral analgesia by non-steroidal anti-inflammatory drug zaltoprofen to manage cystoscopy-related pain: a prospective study. Int J Urol. 2009 Nov;16(11):874-80. doi: 10.1111/j.1442-2042.2009.02384.x. Epub 2009 Sep 24. PubMed PMID: 19780869.
18: Hase K, Kamisako M, Fujiwara T, Tsuji T, Liu M. The effect of zaltoprofen on physiotherapy for limited shoulder movement in breast cancer patients: a single-blinded before-after trial. Arch Phys Med Rehabil. 2006 Dec;87(12):1618-22. PubMed PMID: 17141642.
19: Aher KB, Bhavar GB, Joshi HP, Chaudhari SR. Economical spectrophotometric method for estimation of zaltoprofen in pharmaceutical formulations. Pharm Methods. 2011 Apr;2(2):152-6. doi: 10.4103/2229-4708.84443. PubMed PMID: 23781447; PubMed Central PMCID: PMC3658038.
20: Okamoto T, Kawasaki T, Masuda Y. Zaltoprofen inhibits concanavalin A-induced decrease of body weight in mice. Int J Mol Med. 2001 Sep;8(3):315-7. PubMed PMID: 11494061.
